nodes	percent_of_prediction	percent_of_DWPC	metapath
Naproxen—gout—osteoarthritis	0.786	1	CtDrD
Naproxen—PTGS2—osteoarthritis	0.196	1	CbGaD
Naproxen—AKR1C3—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGES—osteoarthritis	0.00194	0.132	CbGpPWpGaD
Naproxen—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGES—osteoarthritis	0.000845	0.0574	CbGpPWpGaD
Naproxen—AKR1C3—Arachidonic acid metabolism—PTGES—osteoarthritis	0.000701	0.0476	CbGpPWpGaD
Naproxen—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGES—osteoarthritis	0.000671	0.0455	CbGpPWpGaD
Naproxen—PTGS1—Eicosanoid Synthesis—PTGES—osteoarthritis	0.000549	0.0373	CbGpPWpGaD
Naproxen—Indomethacin—CXCL8—osteoarthritis	0.000516	0.167	CrCbGaD
Naproxen—PTGS2—Eicosanoid Synthesis—PTGES—osteoarthritis	0.000436	0.0296	CbGpPWpGaD
Naproxen—Ketoprofen—CXCL8—osteoarthritis	0.000413	0.134	CrCbGaD
Naproxen—Ibuprofen—CXCL8—osteoarthritis	0.000406	0.132	CrCbGaD
Naproxen—Nabumetone—PTGS2—osteoarthritis	0.000401	0.13	CrCbGaD
Naproxen—Carprofen—PTGS2—osteoarthritis	0.000383	0.124	CrCbGaD
Naproxen—AKR1C3—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—osteoarthritis	0.000381	0.0259	CbGpPWpGaD
Naproxen—PTGS1—Arachidonic acid metabolism—PTGES—osteoarthritis	0.000305	0.0207	CbGpPWpGaD
Naproxen—CYP1A2—Tryptophan metabolism—ALDH1A2—osteoarthritis	0.000249	0.0169	CbGpPWpGaD
Naproxen—PTGS2—Arachidonic acid metabolism—PTGES—osteoarthritis	0.000242	0.0164	CbGpPWpGaD
Naproxen—Suprofen—PTGS2—osteoarthritis	0.000237	0.0768	CrCbGaD
Naproxen—UGT2B7—Phase II conjugation—GSTO1—osteoarthritis	0.000207	0.014	CbGpPWpGaD
Naproxen—Fenoprofen—PTGS2—osteoarthritis	0.000204	0.0662	CrCbGaD
Naproxen—CYP2C8—Arachidonic acid metabolism—PTGES—osteoarthritis	0.000197	0.0134	CbGpPWpGaD
Naproxen—PTGS1—Overview of nanoparticle effects—CRP—osteoarthritis	0.000194	0.0131	CbGpPWpGaD
Naproxen—AKR1C3—Metapathway biotransformation—GSTO1—osteoarthritis	0.000181	0.0123	CbGpPWpGaD
Naproxen—PTGS1—Overview of nanoparticle effects—FN1—osteoarthritis	0.000179	0.0121	CbGpPWpGaD
Naproxen—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—MMP1—osteoarthritis	0.000178	0.0121	CbGpPWpGaD
Naproxen—UGT1A1—Phase II conjugation—GSTO1—osteoarthritis	0.000168	0.0114	CbGpPWpGaD
Naproxen—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—osteoarthritis	0.000166	0.0113	CbGpPWpGaD
Naproxen—CYP2C9—Arachidonic acid metabolism—PTGES—osteoarthritis	0.00016	0.0109	CbGpPWpGaD
Naproxen—PTGS2—Overview of nanoparticle effects—CRP—osteoarthritis	0.000154	0.0104	CbGpPWpGaD
Naproxen—Indomethacin—PTGS2—osteoarthritis	0.00015	0.0488	CrCbGaD
Naproxen—PTGS2—Spinal Cord Injury—SOX9—osteoarthritis	0.00015	0.0102	CbGpPWpGaD
Naproxen—PTGS2—Overview of nanoparticle effects—FN1—osteoarthritis	0.000142	0.00963	CbGpPWpGaD
Naproxen—AKR1C3—Arachidonic acid metabolism—PTGS2—osteoarthritis	0.000138	0.00934	CbGpPWpGaD
Naproxen—CYP1A2—Arachidonic acid metabolism—PTGES—osteoarthritis	0.000137	0.00931	CbGpPWpGaD
Naproxen—Flurbiprofen—PTGS2—osteoarthritis	0.000133	0.0432	CrCbGaD
Naproxen—PTGS1—Overview of nanoparticle effects—PTGS2—osteoarthritis	0.00013	0.00881	CbGpPWpGaD
Naproxen—PTGS1—Overview of nanoparticle effects—CXCL8—osteoarthritis	0.000126	0.00855	CbGpPWpGaD
Naproxen—UGT2B7—Biological oxidations—GSTO1—osteoarthritis	0.000121	0.0082	CbGpPWpGaD
Naproxen—Ketoprofen—PTGS2—osteoarthritis	0.00012	0.0391	CrCbGaD
Naproxen—UGT2B7—Metapathway biotransformation—GSTO1—osteoarthritis	0.000119	0.00809	CbGpPWpGaD
Naproxen—Ibuprofen—PTGS2—osteoarthritis	0.000118	0.0384	CrCbGaD
Naproxen—CYP1A2—Estrogen Receptor Pathway—ESR1—osteoarthritis	0.00011	0.00747	CbGpPWpGaD
Naproxen—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—GSTO1—osteoarthritis	0.00011	0.00744	CbGpPWpGaD
Naproxen—PTGS1—Eicosanoid Synthesis—PTGS2—osteoarthritis	0.000108	0.00731	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—PTGES—osteoarthritis	0.0001	0.0068	CbGpPWpGaD
Naproxen—PTGS2—Overview of nanoparticle effects—CXCL8—osteoarthritis	0.0001	0.00679	CbGpPWpGaD
Naproxen—UGT1A1—Biological oxidations—GSTO1—osteoarthritis	9.82e-05	0.00666	CbGpPWpGaD
Naproxen—UGT1A1—Metapathway biotransformation—GSTO1—osteoarthritis	9.68e-05	0.00657	CbGpPWpGaD
Naproxen—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—osteoarthritis	9.01e-05	0.00612	CbGpPWpGaD
Naproxen—PTGS2—Signaling mediated by p38-alpha and p38-beta—ESR1—osteoarthritis	8.81e-05	0.00598	CbGpPWpGaD
Naproxen—PTGS1—Overview of nanoparticle effects—TNF—osteoarthritis	8.77e-05	0.00595	CbGpPWpGaD
Naproxen—PTGS1—Biological oxidations—GSTO1—osteoarthritis	8e-05	0.00543	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—COL2A1—osteoarthritis	7.93e-05	0.00538	CbGpPWpGaD
Naproxen—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—osteoarthritis	7.31e-05	0.00496	CbGpPWpGaD
Naproxen—PTGS2—Aryl Hydrocarbon Receptor—ESR1—osteoarthritis	7.08e-05	0.00481	CbGpPWpGaD
Naproxen—PTGS1—Overview of nanoparticle effects—IL6—osteoarthritis	7.07e-05	0.0048	CbGpPWpGaD
Naproxen—PTGS2—Overview of nanoparticle effects—TNF—osteoarthritis	6.96e-05	0.00472	CbGpPWpGaD
Naproxen—ALB—Platelet degranulation—HSPA5—osteoarthritis	6.73e-05	0.00456	CbGpPWpGaD
Naproxen—AKR1C3—Disease—FMOD—osteoarthritis	6.54e-05	0.00444	CbGpPWpGaD
Naproxen—ALB—Response to elevated platelet cytosolic Ca2+—HSPA5—osteoarthritis	6.41e-05	0.00435	CbGpPWpGaD
Naproxen—ALB—Platelet degranulation—TIMP1—osteoarthritis	6.41e-05	0.00435	CbGpPWpGaD
Naproxen—CYP1A2—Phase II conjugation—GSTO1—osteoarthritis	6.15e-05	0.00417	CbGpPWpGaD
Naproxen—ALB—Response to elevated platelet cytosolic Ca2+—TIMP1—osteoarthritis	6.1e-05	0.00414	CbGpPWpGaD
Naproxen—PTGS1—Arachidonic acid metabolism—PTGS2—osteoarthritis	5.99e-05	0.00406	CbGpPWpGaD
Naproxen—AKR1C3—Disease—IHH—osteoarthritis	5.83e-05	0.00395	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—PTGES—osteoarthritis	5.73e-05	0.00389	CbGpPWpGaD
Naproxen—PTGS1—Selenium Micronutrient Network—CRP—osteoarthritis	5.68e-05	0.00386	CbGpPWpGaD
Naproxen—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—osteoarthritis	5.68e-05	0.00385	CbGpPWpGaD
Naproxen—ALB—Vitamin B12 Metabolism—CRP—osteoarthritis	5.64e-05	0.00383	CbGpPWpGaD
Naproxen—PTGS2—Overview of nanoparticle effects—IL6—osteoarthritis	5.62e-05	0.00381	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—FMOD—osteoarthritis	5.47e-05	0.00372	CbGpPWpGaD
Naproxen—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—osteoarthritis	5.3e-05	0.0036	CbGpPWpGaD
Naproxen—CYP2C8—Biological oxidations—GSTO1—osteoarthritis	5.17e-05	0.00351	CbGpPWpGaD
Naproxen—CYP2C8—Metapathway biotransformation—GSTO1—osteoarthritis	5.1e-05	0.00346	CbGpPWpGaD
Naproxen—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—osteoarthritis	4.61e-05	0.00313	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—CRP—osteoarthritis	4.59e-05	0.00312	CbGpPWpGaD
Naproxen—PTGS2—Selenium Micronutrient Network—CRP—osteoarthritis	4.51e-05	0.00306	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PTGES—osteoarthritis	4.46e-05	0.00303	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PTGES—osteoarthritis	4.36e-05	0.00296	CbGpPWpGaD
Naproxen—AKR1C3—Disease—TGFBI—osteoarthritis	4.34e-05	0.00295	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—IL1A—osteoarthritis	4.27e-05	0.0029	CbGpPWpGaD
Naproxen—CYP2C9—Biological oxidations—GSTO1—osteoarthritis	4.21e-05	0.00286	CbGpPWpGaD
Naproxen—CYP2C9—Metapathway biotransformation—GSTO1—osteoarthritis	4.15e-05	0.00282	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—IHH—osteoarthritis	4.08e-05	0.00277	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MCF2L—osteoarthritis	4.08e-05	0.00277	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—osteoarthritis	4.01e-05	0.00272	CbGpPWpGaD
Naproxen—CYP2C8—Arachidonic acid metabolism—PTGS2—osteoarthritis	3.87e-05	0.00263	CbGpPWpGaD
Naproxen—PTGS1—Selenium Micronutrient Network—PTGS2—osteoarthritis	3.81e-05	0.00259	CbGpPWpGaD
Naproxen—AKR1C3—Disease—GSTO1—osteoarthritis	3.75e-05	0.00255	CbGpPWpGaD
Naproxen—ALB—Selenium Micronutrient Network—CRP—osteoarthritis	3.65e-05	0.00248	CbGpPWpGaD
Naproxen—AKR1C3—Disease—BGN—osteoarthritis	3.64e-05	0.00247	CbGpPWpGaD
Naproxen—ALB—Platelet degranulation—FN1—osteoarthritis	3.63e-05	0.00247	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—FMOD—osteoarthritis	3.6e-05	0.00244	CbGpPWpGaD
Naproxen—CYP1A2—Biological oxidations—GSTO1—osteoarthritis	3.6e-05	0.00244	CbGpPWpGaD
Naproxen—CYP1A2—Metapathway biotransformation—GSTO1—osteoarthritis	3.55e-05	0.00241	CbGpPWpGaD
Naproxen—PTGS1—Selenium Micronutrient Network—IL1B—osteoarthritis	3.54e-05	0.00241	CbGpPWpGaD
Naproxen—ALB—Vitamin B12 Metabolism—IL1B—osteoarthritis	3.52e-05	0.00239	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—LEP—osteoarthritis	3.49e-05	0.00237	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PTGES—osteoarthritis	3.46e-05	0.00235	CbGpPWpGaD
Naproxen—ALB—Response to elevated platelet cytosolic Ca2+—FN1—osteoarthritis	3.46e-05	0.00235	CbGpPWpGaD
Naproxen—PTGS2—Aryl Hydrocarbon Receptor—TNF—osteoarthritis	3.43e-05	0.00233	CbGpPWpGaD
Naproxen—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—osteoarthritis	3.21e-05	0.00218	CbGpPWpGaD
Naproxen—ALB—Platelet degranulation—IGF1—osteoarthritis	3.18e-05	0.00216	CbGpPWpGaD
Naproxen—CYP2C9—Arachidonic acid metabolism—PTGS2—osteoarthritis	3.15e-05	0.00214	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—GSTO1—osteoarthritis	3.14e-05	0.00213	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—FMOD—osteoarthritis	3.13e-05	0.00213	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—BGN—osteoarthritis	3.05e-05	0.00207	CbGpPWpGaD
Naproxen—ALB—Response to elevated platelet cytosolic Ca2+—IGF1—osteoarthritis	3.03e-05	0.00206	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—COL9A2—osteoarthritis	2.99e-05	0.00203	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—HSPA5—osteoarthritis	2.98e-05	0.00202	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PTGES—osteoarthritis	2.93e-05	0.00199	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—FMOD—osteoarthritis	2.92e-05	0.00198	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—COL9A1—osteoarthritis	2.91e-05	0.00197	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—osteoarthritis	2.88e-05	0.00195	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—IL1B—osteoarthritis	2.87e-05	0.00194	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—TIMP1—osteoarthritis	2.84e-05	0.00193	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PTGES—osteoarthritis	2.82e-05	0.00191	CbGpPWpGaD
Naproxen—PTGS2—Selenium Micronutrient Network—IL1B—osteoarthritis	2.81e-05	0.00191	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PTGES—osteoarthritis	2.8e-05	0.0019	CbGpPWpGaD
Naproxen—UGT2B7—NRF2 pathway—TGFB1—osteoarthritis	2.77e-05	0.00188	CbGpPWpGaD
Naproxen—CYP1A2—Arachidonic acid metabolism—PTGS2—osteoarthritis	2.69e-05	0.00183	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—osteoarthritis	2.68e-05	0.00182	CbGpPWpGaD
Naproxen—PTGS1—Selenium Micronutrient Network—TNF—osteoarthritis	2.57e-05	0.00175	CbGpPWpGaD
Naproxen—ALB—Vitamin B12 Metabolism—TNF—osteoarthritis	2.56e-05	0.00173	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PTGES—osteoarthritis	2.55e-05	0.00173	CbGpPWpGaD
Naproxen—ALB—Selenium Micronutrient Network—PTGS2—osteoarthritis	2.45e-05	0.00166	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—FMOD—osteoarthritis	2.38e-05	0.00162	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PTGES—osteoarthritis	2.38e-05	0.00162	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—CXCL8—osteoarthritis	2.32e-05	0.00157	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PTGES—osteoarthritis	2.29e-05	0.00156	CbGpPWpGaD
Naproxen—ALB—Selenium Micronutrient Network—IL1B—osteoarthritis	2.28e-05	0.00154	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—osteoarthritis	2.27e-05	0.00154	CbGpPWpGaD
Naproxen—PTGS2—Disease—FMOD—osteoarthritis	2.26e-05	0.00153	CbGpPWpGaD
Naproxen—UGT1A1—NRF2 pathway—TGFB1—osteoarthritis	2.25e-05	0.00153	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—IL1B—osteoarthritis	2.22e-05	0.00151	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—MMP9—osteoarthritis	2.1e-05	0.00142	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—TNF—osteoarthritis	2.08e-05	0.00141	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—osteoarthritis	2.08e-05	0.00141	CbGpPWpGaD
Naproxen—PTGS1—Selenium Micronutrient Network—IL6—osteoarthritis	2.08e-05	0.00141	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—GSTO1—osteoarthritis	2.07e-05	0.0014	CbGpPWpGaD
Naproxen—ALB—Vitamin B12 Metabolism—IL6—osteoarthritis	2.06e-05	0.0014	CbGpPWpGaD
Naproxen—PTGS2—Selenium Micronutrient Network—TNF—osteoarthritis	2.04e-05	0.00139	CbGpPWpGaD
Naproxen—PTGS2—Disease—IHH—osteoarthritis	2.01e-05	0.00137	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—BGN—osteoarthritis	2e-05	0.00136	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—BMP2—osteoarthritis	1.99e-05	0.00135	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—PTGS2—osteoarthritis	1.97e-05	0.00133	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—osteoarthritis	1.96e-05	0.00133	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PTGES—osteoarthritis	1.96e-05	0.00133	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PTGES—osteoarthritis	1.94e-05	0.00132	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—osteoarthritis	1.94e-05	0.00132	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—TNF—osteoarthritis	1.94e-05	0.00132	CbGpPWpGaD
Naproxen—ALB—Platelet degranulation—TGFB1—osteoarthritis	1.91e-05	0.0013	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—FMOD—osteoarthritis	1.89e-05	0.00128	CbGpPWpGaD
Naproxen—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—osteoarthritis	1.82e-05	0.00123	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—GSTO1—osteoarthritis	1.8e-05	0.00122	CbGpPWpGaD
Naproxen—AKR1C3—Disease—SMAD3—osteoarthritis	1.79e-05	0.00121	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—BGN—osteoarthritis	1.74e-05	0.00118	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—TGFB1—osteoarthritis	1.73e-05	0.00117	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—GSTO1—osteoarthritis	1.68e-05	0.00114	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—IL6—osteoarthritis	1.68e-05	0.00114	CbGpPWpGaD
Naproxen—ALB—Selenium Micronutrient Network—TNF—osteoarthritis	1.65e-05	0.00112	CbGpPWpGaD
Naproxen—PTGS2—Selenium Micronutrient Network—IL6—osteoarthritis	1.65e-05	0.00112	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—BGN—osteoarthritis	1.63e-05	0.0011	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—TNF—osteoarthritis	1.61e-05	0.0011	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—FN1—osteoarthritis	1.61e-05	0.00109	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PTGES—osteoarthritis	1.54e-05	0.00105	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—FMOD—osteoarthritis	1.54e-05	0.00104	CbGpPWpGaD
Naproxen—ALB—Hemostasis—HSPA5—osteoarthritis	1.54e-05	0.00104	CbGpPWpGaD
Naproxen—ALB—Metabolism—FMOD—osteoarthritis	1.53e-05	0.00104	CbGpPWpGaD
Naproxen—PTGS2—Disease—TGFBI—osteoarthritis	1.5e-05	0.00102	CbGpPWpGaD
Naproxen—ALB—Hemostasis—TIMP1—osteoarthritis	1.46e-05	0.000994	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—IGF1—osteoarthritis	1.41e-05	0.000959	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MMP3—osteoarthritis	1.38e-05	0.000937	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—GSTO1—osteoarthritis	1.37e-05	0.000929	CbGpPWpGaD
Naproxen—ALB—Selenium Micronutrient Network—IL6—osteoarthritis	1.33e-05	0.000905	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—BGN—osteoarthritis	1.33e-05	0.0009	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—IL6—osteoarthritis	1.3e-05	0.000884	CbGpPWpGaD
Naproxen—PTGS2—Disease—GSTO1—osteoarthritis	1.3e-05	0.000881	CbGpPWpGaD
Naproxen—PTGS2—Disease—BGN—osteoarthritis	1.26e-05	0.000853	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PTGES—osteoarthritis	1.25e-05	0.000852	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—FMOD—osteoarthritis	1.25e-05	0.00085	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—SMAD3—osteoarthritis	1.25e-05	0.000848	CbGpPWpGaD
Naproxen—ALB—Metabolism—PTGES—osteoarthritis	1.25e-05	0.000847	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—osteoarthritis	1.18e-05	0.000798	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—osteoarthritis	1.12e-05	0.000764	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—osteoarthritis	1.1e-05	0.000745	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GSTO1—osteoarthritis	1.09e-05	0.000738	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—FMOD—osteoarthritis	1.07e-05	0.000727	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—LEP—osteoarthritis	1.07e-05	0.000725	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—BGN—osteoarthritis	1.05e-05	0.000714	CbGpPWpGaD
Naproxen—AKR1C3—Disease—PTGS2—osteoarthritis	1.05e-05	0.00071	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PTGES—osteoarthritis	1.02e-05	0.000693	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—ESR1—osteoarthritis	1.02e-05	0.000692	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—FN1—osteoarthritis	1.01e-05	0.000684	CbGpPWpGaD
Naproxen—ALB—Hemostasis—MMP1—osteoarthritis	9.11e-06	0.000618	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GSTO1—osteoarthritis	8.84e-06	0.0006	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—IGF1—osteoarthritis	8.83e-06	0.000599	CbGpPWpGaD
Naproxen—ALB—Metabolism—GSTO1—osteoarthritis	8.79e-06	0.000597	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PTGS2—osteoarthritis	8.76e-06	0.000594	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PTGES—osteoarthritis	8.73e-06	0.000592	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—BGN—osteoarthritis	8.56e-06	0.000581	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—osteoarthritis	8.56e-06	0.000581	CbGpPWpGaD
Naproxen—ALB—Metabolism—BGN—osteoarthritis	8.51e-06	0.000578	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—TGFB1—osteoarthritis	8.47e-06	0.000575	CbGpPWpGaD
Naproxen—ALB—Hemostasis—FN1—osteoarthritis	8.31e-06	0.000564	CbGpPWpGaD
Naproxen—AKR1C3—Disease—TGFB1—osteoarthritis	7.56e-06	0.000513	CbGpPWpGaD
Naproxen—ALB—Hemostasis—IGF1—osteoarthritis	7.28e-06	0.000494	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GSTO1—osteoarthritis	7.2e-06	0.000488	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CXCL8—osteoarthritis	7.1e-06	0.000482	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—BGN—osteoarthritis	6.97e-06	0.000473	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MMP9—osteoarthritis	6.42e-06	0.000436	CbGpPWpGaD
Naproxen—PTGS2—Disease—SMAD3—osteoarthritis	6.17e-06	0.000419	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GSTO1—osteoarthritis	6.15e-06	0.000417	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—BGN—osteoarthritis	5.96e-06	0.000404	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PTGS2—osteoarthritis	5.75e-06	0.00039	CbGpPWpGaD
Naproxen—AKR1C3—Disease—IL6—osteoarthritis	5.7e-06	0.000387	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—osteoarthritis	5.53e-06	0.000375	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PTGS2—osteoarthritis	5.5e-06	0.000373	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TGFB1—osteoarthritis	5.29e-06	0.000359	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PTGS2—osteoarthritis	5.01e-06	0.00034	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PTGS2—osteoarthritis	4.68e-06	0.000317	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—osteoarthritis	4.5e-06	0.000305	CbGpPWpGaD
Naproxen—ALB—Hemostasis—TGFB1—osteoarthritis	4.36e-06	0.000296	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—IL6—osteoarthritis	3.99e-06	0.000271	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—osteoarthritis	3.84e-06	0.000261	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PTGS2—osteoarthritis	3.81e-06	0.000259	CbGpPWpGaD
Naproxen—PTGS2—Disease—TGFB1—osteoarthritis	2.61e-06	0.000177	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PTGS2—osteoarthritis	2.46e-06	0.000167	CbGpPWpGaD
Naproxen—ALB—Metabolism—PTGS2—osteoarthritis	2.45e-06	0.000166	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PTGS2—osteoarthritis	2e-06	0.000136	CbGpPWpGaD
Naproxen—PTGS2—Disease—IL6—osteoarthritis	1.97e-06	0.000134	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PTGS2—osteoarthritis	1.71e-06	0.000116	CbGpPWpGaD
